TIDMBGC TIDMBII
RNS Number : 2132A
BTG PLC
27 January 2011
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
IN, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION
London, 27 January 2011
BTG PLC ("BTG")
Acquisition of Biocompatibles International plc
("Biocompatibles")
Offer Update: Scheme Effective
BTG, the specialist pharmaceuticals company, is pleased to
announce that the Court Orders have today been delivered to the
Registrar of Companies and the Scheme has therefore become
effective.
Biocompatibles has made an application to the London Stock
Exchange for the cancellation of the admission to trading of
Biocompatibles Shares on its main market for listed securities and
to the UK Listing Authority for the cancellation of the admission
of the Biocompatibles Shares to the Official List, in each case to
be effective from 8:00 a.m. (London time) tomorrow, 28 January
2011.
BTG will make applications to the London Stock Exchange and the
UK Listing Authority in respect of the Admission of the New BTG
Shares from 8.00 a.m. (London time) tomorrow, 28 January 2011.
Terms defined in the Scheme Document shall have the same
meaning(s) when used in this announcement.
A copy of this announcement will be available on the Company's
website at www.btgplc.com by no later than 12:00 noon (London time)
on 28 January 2011 (subject to certain restrictions relating to
persons resident in restricted jurisdictions).
For further information contact:
BTG
Louise Makin, Chief Executive Officer
+44 (0) 20 7575 0000
Andy Burrows, Director of Investor Relations +44 (0)20 7575 1741
+44 (0)7990 530605 (mobile)
Rolf Soderstrom, Chief Financial Officer +44 (0)20 7575 0000
Financial Dynamics Ben Atwell +44 (0)20 7831 3113
Rothschild (financial adviser and joint sponsor to BTG)
Dominic Hollamby
+44 (0)20 7280 5000
Julian Hudson
+44 (0)20 7280 5000
J.P. Morgan Cazenove (joint sponsor and corporate broker to
BTG)
James Mitford
+44 (0)20 7742 4000
Gina Gibson
+44 (0)20 7742 4000
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQPGUCUGUPGGAM